Omnicell reports Q4 non-GAAP EPS 50c, consensus 58c

Reports Q4 revenue $307M, consensus $300.01M. “We delivered solid financial results for Q4 2024, including returning to year-over-year revenue growth. We are pleased with the improved execution of the business throughout 2024, including strong free cash flows achieved in the year,” stated CEO Randall Lipps. “As we progress through 2025, we remain focused on successfully executing on our strategic priorities, which include driving long-term revenue growth, achieving consistent GAAP profitability, and continuing to raise the bar in medication management and adherence through innovation and bringing new products and services to market.”